Generic versions of Sofusbuvir launched in India

Some good news on the Hep C front - Gilead has licenced Cipla, Natco Pharma and Zydus to launch its patented drug molecule, Sofusbuvir (Sovaldi), in India at prices that are a fraction of the cost in the US. Although it will still not be a cheap drug, at least most patients will be able to afford it either directly or through the help of some charitable organisations that have been working in this field.

http://www.dnaindia.com/money/report-cipla-to-launch-generic-hepatitis-c-drug-hepcvir-in-india-2071842
http://www.dnaindia.com/money/report-natco-wins-india-regulator-nod-for-sovaldi-generic-2068384
http://www.dnaindia.com/mumbai/report-hepatitis-c-drug-from-rs-18-crore-to-rs-12-lakh-2073038


Poirot

Poirot,

This is good sign Gilead showing. 12 million in India that's huge I have seen unauthenticated may be over exaggerated posts related to the Hep C infection in Pakistan dangerously high.
In India I fear most for Hep C, Human errors and close minded doctors.

something interesting to watch http://www.ted.com/talks/thomas_pogge_medicine_for_the_99_percent